GlassScriptPhysician profile
Ryan J Townsend
NPI 1194188375
$2,769.21
in general payments reported to CMS, 2019-2025
27 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $199 · 2024: $795 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,554 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.05 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $667.31 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $487.84 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Inspire Medical Systems, INC. | $176.11 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $155.54 | 2024-2025 | Dupixent |
| Genzyme Corporation | $139.94 | 2023-2025 | |
| Philips North America LLC | $136.24 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $127.63 | 2024-2025 | Aralast |
| Grifols USA, LLC | $109.36 | 2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $97.52 | 2024-2025 | Uptravi, Opsumit |
| Verona Pharma, INC. | $94.80 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $54.81 | 2024-2025 | |
| Mylan Specialty L.P. | $49.96 | 2022-2024 | Yupelri |
| Baxter Healthcare | $46.77 | 2025 | |
| Ani Pharmaceuticals, INC. | $42.65 | 2025 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39.30 | 2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.44 | 2024-2025 | Ofev |
| Harmony Biosciences LLC | $35.15 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $31.90 | 2023 | |
| Vapotherm INC | $26.67 | 2024 | Vapotherm |
| Resmed Corp | $18.30 | 2025 | |
| Insmed, INC. | $18.12 | 2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2024 | |
| Axsome Therapeutics, INC. | $16.25 | 2025 | Sunosi |
| Azurity Pharmaceuticals, INC. | $15.57 | 2025 | Horizant |
| Avadel Cns Pharmaceuticals, LLC | $14.97 | 2024 | Lumryz |
| Gilead Sciences, INC. | $14.11 | 2024 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.